HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
west CLINICAL TRIALS

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

          RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
        

Est. Enrollment: 80 participants

info
The number of participants in a clinical study. The "estimated" enrollment is the target number of participants the researchers need for the study.

Study Start Date: Sep 01, 2009

info
These are the dates the researchers think the study will start and end.

Study Completion Date: Dec 01, 2023

info
The "estimated" study completion date is the date the researchers think the last participant in a clinical study was examined or received an intervention/treatment. This is also the expected date that the study will be completed

Age: 18 to 120 years

Gender: All

Study Description expand_more
Study Details expand_more

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube